Check out your Company Bowl for anonymous work chats.
September is both Childhood Cancer Awareness Month and Blood Cancer Awareness Month. For pediatric oncologist, SVP Lanny Kirsch, it’s a time to celebrate how far we’ve come and reflect on how much further we have to go to advance cancer treatments.
Chief Medical Officer Lance Baldo sat down with Shikha Jain to discuss the latest in MRD testing, T-cell receptor profiling and how lessons learned from COVID-19 vaccine development may impact the future of cancer vaccines. Listen in at https://rebrand.ly/a6lbydd.
Extending Our Immune Medicine Platform: How T Cells Can Be Used in the Design and Development of Next-Generation Vaccines
T Cells: The Unsung Heroes of the Immune System
Celebrating Our Lab Professionals During Medical Laboratory Professionals Week – and Every Week
We’ve received FDA Emergency Use Authorization for T-Detect™ COVID, the first T cell-based test to confirm recent or prior #COVID19 infection, developed in collaboration with Microsoft:
At Adaptive Biotechnologies, we’ve spent over a decade building our proprietary immune medicine platform to decode the adaptive immune system to learn how it naturally detects and fights a multitude of diseases. Through a collaboration with Microsoft, we are using our platform and Microsoft’s AI and Machine Learning to develop a TCR-antigen map, a map of T cells, the first responders of the adaptive immune system to the antigens they bind. Using this data, we aim to translate the natural diagnostic capability of the immune system into the clinic. When the pandemic hit, we turned our platform to COVID, to develop the first-ever T cell-based clinical test that can detect an immune response to recent or past COVID infection.
New Minimal Residual Disease (MRD) Research is Great News for Blood Cancer Patients
T Cell Testing Outperforms Antibody Testing in Determining Prior COVID-19 Infection
Adaptive Biotech has taken another step in the evolution of our company – a new brand identity, and a new symbol: The Adaptive A.
